Pentamidine isethionate

Discontinued Product

3277 has been discontinued.

View all NMDA Receptors products.
说明: NMDA antagonist: antimicrobial
化学名: 4,4'-(Pentamethylenedioxy)dibenzamidine bis-2-hydroxyethanesulfonate salt
纯度: ≥99% (HPLC)
说明书
引用文献 (1)
评论
文献 (5)

生物活性 for Pentamidine isethionate

Pentamidine isethionate is an antimicrobial. Neuroprotective; inhibits constitutive nitric oxide synthase in the brain and acts as a NMDA glutamate receptor antagonist.

技术数据 for Pentamidine isethionate

分子量 592.68
公式 C19H24N4O2.2C2H6O4S
储存 Store at -20°C
纯度 ≥99% (HPLC)
CAS Number 140-64-7
PubChem ID 8813
InChI Key YBVNFKZSMZGRAD-UHFFFAOYSA-N
Smiles NC(C1=CC=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=N.OCCS(=O)(O)=O.OCCS(=O)(O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Pentamidine isethionate

参考文献 for Pentamidine isethionate

参考文献是支持产品生物活性的出版物。

Reynolds and Aizeman (1992) Pentamidine is an N-MthD.-aspartate receptor antagonist and is neuroprotective in vitro. J.Neurosci. 12 970 PMID: 1532027

Kitamura et al (1995) Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist. Eur.J.Pharmacol. 289 299 PMID: 7542607

按产品操作查看相关产品

查看全部 NMDA Receptor Antagonists

关键词: Pentamidine isethionate, Pentamidine isethionate supplier, Antimicrobial, inhibits, inhibitors, constitutive, nNOS, NMDA, antagonist, receptors, Nitric, Oxide, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Neuronal, oxide, Synthases, Miscellaneous, Compounds, 3277, Tocris Bioscience

1 篇 Pentamidine isethionate 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Pentamidine isethionate 的部分引用包括:

Capoccia et al (2015) S100B-p53 disengagement by pentam. promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncol Lett 9 2864 PMID: 26137161


Pentamidine isethionate 的评论

目前没有该产品的评论。 Be the first to review Pentamidine isethionate and earn rewards!

Have you used Pentamidine isethionate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.